Medicine Recommendations

Treating diabetic macular oedema - NICE TA820

NICE TA820 - Brolucizumab for treating diabetic macular oedema

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

For induction of remission in adults with mild to moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient.

For inducing remission of eosinophilic oesophagitis. 

NICE TA 708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis

Refer to LSCMMG COPD Guidelines (link below)

Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).

Anxiety (short term use)

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Hyperprolactinaemia

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Psoriasis

Hypercalcaemia

Prevention of sudden bone loss due to sudden immobility

Hyperphosphataemia associated with renal failure

Phosphate binder - Renal Dialysis

Following a Gastric Bypass

Following Bariatric Surgery Performed Privately

Following a sleeve Gastrectomy

Methotrexate induced mucosistis or myelosuppression

 In combination therapy for treating type 2 diabetes (NICE TA315)

NICE TA315 - Canagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)